Nomura/Instinet initiates coverage on Redhill Biopharma (NASDAQ: RDHL) with a Buy rating and a price target of $18.00.Analyst Chris Marai ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE